GlassScriptPhysician profile
Charles Accurso
NPI 1710963533
$2,126.01
in general payments reported to CMS, 2019-2025
21 companies · $749 in 2025
The $749 reported for 2025 was more than what 85% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $195 · 2020: $134 · 2021: $179 · 2022: $265 · 2023: $241 · 2024: $363 · 2025: $749.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,310 · Long Term Medical Supply Or Device Loan: $42.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,310.10 |
| Long Term Medical Supply Or Device Loan | $42.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $794.94 | 2019-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $283.88 | 2019-2023 | Stelara |
| Genzyme Corporation | $196.27 | 2023-2025 | |
| Madrigal Pharmaceuticals | $125.37 | 2025 | Rezdiffra |
| Novo Nordisk INC | $117.76 | 2025 | Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $95.37 | 2019-2025 | Entyvio, Eohilia |
| Lilly USA, LLC | $92.25 | 2024-2025 | Omvoh |
| Ironwood Pharmaceuticals, INC | $67.11 | 2021-2024 | Linzess |
| Ethicon US, LLC | $45.13 | 2019-2021 | |
| Ardelyx, INC. | $44.49 | 2023-2024 | Ibsrela |
| Pentax of America, INC. | $42.38 | 2024 | Endo Stratus Co2 Insufflator |
| Pfizer INC. | $41.78 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.73 | 2020-2023 | Xifaxan |
| Allergan, INC. | $26.17 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $20.15 | 2024 | Bylvay |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi US Services INC. | $19.27 | 2025 | |
| Daiichi Sankyo INC. | $15.00 | 2022 | |
| Merck Sharp & Dohme LLC | $14.99 | 2021 | |
| Celgene Corporation | $14.53 | 2022 | |
| Qol Medical, LLC | $13.73 | 2019 | |
| Medtronic, INC. | $13.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Accurso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.